Journal
CELL DEATH AND DIFFERENTIATION
Volume 19, Issue 1, Pages 58-66Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2011.163
Keywords
RIPK1; RIP1; IAP; apoptosis
Categories
Funding
- NHS
- Apoptosis Lab
Ask authors/readers for more resources
Deregulation of innate immune signalling and cell death form the basis of most human disease pathogenesis. Inhibitor of APoptosis (IAP) protein-family members are frequently overexpressed in cancer and contribute to tumour cell survival, chemoresistance, disease progression and poor prognosis. Although best known for their ability to regulate caspases, IAPs also influence ubiquitin-dependent pathways that modulate innate immune signalling by activation of NF-kappa B. Recent advances in our understanding of the molecular mechanisms through which IAPs influence cell death and innate immune responses have provided new insights into novel strategies for treatment of cancer. In this review we discuss our current understanding of IAP-mediated NF-kappa B signalling, as well as elaborate on unexpected insights into the involvement of IAPs in regulating the 'Ripoptosome', a novel intrinsic cell death-inducing platform. We propose an evolutionarily conserved concept whereby IAPs function as guardians of killer platforms such as the apoptosome in Drosophila and the Ripoptosome in mammals. Cell Death and Differentiation (2012) 19, 58-66; doi:10.1038/cdd.2011.163; published online 18 November 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available